DVAX

Dynavax Technologies Corporation (DVAX), based in Emeryville, California, is a biopharmaceutical leader specializing in the development and commercialization of groundbreaking vaccines designed to tackle significant public health challenges. The company has established itself through its innovative immunotherapy platform, notably with its flagship product, HEPLISAV-B, an advanced hepatitis B vaccine that has received approval in the U.S. and numerous international markets. With a robust pipeline of future products and strategic partnerships, Dynavax is positioned to make substantial contributions to global health by enhancing vaccine efficacy and addressing unmet medical needs. Its dedication to innovation and technology advancement establishes it as a pivotal entity within the dynamic vaccine industry.